SOURCE: Implant Sciences

Implant Sciences

November 21, 2011 07:00 ET

Implant Sciences' Quantum Sniffer™ Explosives Trace Detector to Be Used in New Mobile Airfreight Screening Business in Germany

WILMINGTON, MA--(Marketwire - Nov 21, 2011) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced the first sale of its Quantum Sniffer™ QS-H150 explosives trace detector into Germany by the Company's Hamburg-based distributor, D-TeC System Consulting GmbH.

The QS-H150 handheld explosives trace detector will be used in a completely new security application. The purchasing customer in Germany, First Class Zollservice, intends to provide explosives trace detection services on a fee-per-piece basis to air freight forwarders. The Quantum Sniffer will be installed into a vehicle which will drive to freight forwarding facilities to provide mobile air freight screening services.

"We are proud to see the portability, flexibility, and reliability of our QS-H150 help create cost-effective new business models for security providers. By screening at the air freight forwarder, an additional layer of security and confidence is created before packages even reach the airport," stated Glenn D. Bolduc, President and CEO of Implant Sciences.

"D-TeC System Consulting has been both effective and innovative in the German market for us. The development of our distribution channels continues to build our revenue stream," concluded Bolduc.

About the Quantum Sniffer™ QS-H150

The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer™ QS-B220

The QS-B220, introduced in May 2011, is a benchtop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures, and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed innovative proprietary technologies used in its explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences products have been deployed in a wide range of security environments including airports, subways, railways, cargo facilities, nuclear power plants, police departments, military units, government buildings, and financial institutions. The QS-H150 and QS-B220 are Department of Homeland Security (DHS) Qualified Anti-Terrorism Technologies under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact